These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26096539)

  • 21. Inflammasome signaling and regulation of interleukin-1 family cytokines.
    Chan AH; Schroder K
    J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31611248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that NF-κB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke.
    Fann DY; Lim YA; Cheng YL; Lok KZ; Chunduri P; Baik SH; Drummond GR; Dheen ST; Sobey CG; Jo DG; Chen CL; Arumugam TV
    Mol Neurobiol; 2018 Feb; 55(2):1082-1096. PubMed ID: 28092085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The systemic and local acute phase response following acute brain injury.
    Wilcockson DC; Campbell SJ; Anthony DC; Perry VH
    J Cereb Blood Flow Metab; 2002 Mar; 22(3):318-26. PubMed ID: 11891437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory Roles of Flavonoids on Inflammasome Activation during Inflammatory Responses.
    Yi YS
    Mol Nutr Food Res; 2018 Jul; 62(13):e1800147. PubMed ID: 29774640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of IL-37- and IL-37-Treated Dendritic Cells in Acute Coronary Syndrome.
    Zhu R; Zhang F; Pan C; Yu K; Zhong Y; Zeng Q
    Oxid Med Cell Longev; 2021; 2021():6454177. PubMed ID: 34471467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NLRP3 inflammasome: a potential therapeutic target for traumatic brain injury.
    Ismael S; Ahmed HA; Adris T; Parveen K; Thakor P; Ishrat T
    Neural Regen Res; 2021 Jan; 16(1):49-57. PubMed ID: 32788447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.
    Anders HJ
    J Am Soc Nephrol; 2016 Sep; 27(9):2564-75. PubMed ID: 27516236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses.
    Bachstetter AD; Zhou Z; Rowe RK; Xing B; Goulding DS; Conley AN; Sompol P; Meier S; Abisambra JF; Lifshitz J; Watterson DM; Van Eldik LJ
    PLoS One; 2016; 11(2):e0149451. PubMed ID: 26871438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury.
    Vink R; Van Den Heuvel C
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1263-74. PubMed ID: 15461556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of the heparan sulfate proteoglycan, perlecan, by injury and interleukin-1alpha.
    García de Yébenes E; Ho A; Damani T; Fillit H; Blum M
    J Neurochem; 1999 Aug; 73(2):812-20. PubMed ID: 10428080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes.
    Jones NC; Prior MJ; Burden-Teh E; Marsden CA; Morris PG; Murphy S
    Eur J Neurosci; 2005 Jul; 22(1):72-8. PubMed ID: 16029197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in mechanisms for NLRP3 inflammasomes regulation].
    Liu W; Guo WJ; Xu Q; Sun Y
    Yao Xue Xue Bao; 2016 Oct; 51(10):1505-12. PubMed ID: 29924571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting the Inflammasome: A Chemical Perspective.
    Baldwin AG; Brough D; Freeman S
    J Med Chem; 2016 Mar; 59(5):1691-710. PubMed ID: 26422006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Role of the NLRP3 Inflammasome and Interleukin-1β in Neonates.
    Omer M; Melo AM; Kelly L; Mac Dermott EJ; Leahy TR; Killeen O; Saugstad OD; Savani RC; Molloy EJ
    Neonatology; 2020; 117(5):545-554. PubMed ID: 33075792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory cytokine receptor blockade in a rodent model of mild traumatic brain injury.
    Perez-Polo JR; Rea HC; Johnson KM; Parsley MA; Unabia GC; Xu GY; Prough D; DeWitt DS; Paulucci-Holthauzen AA; Werrbach-Perez K; Hulsebosch CE
    J Neurosci Res; 2016 Jan; 94(1):27-38. PubMed ID: 26172557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the inflammasome in rheumatic diseases.
    McCoy SS; Stannard J; Kahlenberg JM
    Transl Res; 2016 Jan; 167(1):125-37. PubMed ID: 26118952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of traumatic brain injury with anti-inflammatory drugs.
    Bergold PJ
    Exp Neurol; 2016 Jan; 275 Pt 3(Pt 3):367-380. PubMed ID: 26112314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of Inflammasomes by Pathogens Regulates Inflammation.
    Garib FY; Rizopulu AP; Kuchmiy AA; Garib VF
    Biochemistry (Mosc); 2016 Nov; 81(11):1326-1339. PubMed ID: 27914458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms and functions of inflammasomes.
    Lamkanfi M; Dixit VM
    Cell; 2014 May; 157(5):1013-22. PubMed ID: 24855941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exogenous nanoparticles and endogenous crystalline molecules as danger signals for the NLRP3 inflammasomes.
    Shirasuna K; Karasawa T; Takahashi M
    J Cell Physiol; 2019 May; 234(5):5436-5450. PubMed ID: 30370619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.